Peripheral Neuropathy

Medical Clinics of North America

Volumn 93, Issue 2, 2009, Pages 317-342

  Pascuzzi, Robert M ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Charcot Marie Tooth disease; CIDP; Guillain Barr syndrome; Peripheral neuropathy; POEMS

Indexed keywords

IMMUNOGLOBULIN; METHYLPREDNISOLONE; PLACEBO;

BLOOD EXAMINATION; CAMPYLOBACTER ENTERITIS; CEREBROSPINAL FLUID ANALYSIS; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL PRACTICE; DEMYELINATING NEUROPATHY; DIABETIC NEUROPATHY; DIFFERENTIAL DIAGNOSIS; DRUG MEGADOSE; GUILLAIN BARRE SYNDROME; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; IMMUNOTHERAPY; LABORATORY TEST; MONONEUROPATHY; MOTOR NEUROPATHY; NEUROPATHIC PAIN; PATHOPHYSIOLOGY; PATIENT CARE; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SENSORY NEUROPATHY; TREATMENT DURATION; TRIGEMINUS NEURALGIA;

ADULT; CAMPYLOBACTER INFECTIONS; DIABETIC NEUROPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; POLYNEUROPATHIES; QUADRIPLEGIA; YOUNG ADULT;

EID: 61549140356     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2008.12.001     Document Type: Review

References (91)

1. Landry O. Note sur la paralysie ascendante aigue. Gazette Hebd 6 (1859) 472-474
2. Guillain G, Barré JA, Strohl A. Sur un syndrome de radicu-lo-nevrite avec hyperalbuminose du liquide cephalo-rachidien sans reaction cellulaire. Remarques sur les caracteres clinques et graphiques des reflexes tendineux. Bulletins et memories de la societe medicale des hopitaux de Paris. Paris: Masson et Cie 1916;40:1462-70.
3. Guillain G, Barré JA. Travaux neurologiques de guerre. Masson et Cie (Paris), 1920.
4. Fisher C.M. An unusual variant of acute idiopathic polyneuritis syndrome of ophthalmoplegia, ataxia and areflexia. N Engl J Med 255 (1956) 57-65
5. Haymaker W., and Kernohan J.W. The Landry-Guillain-Barre syndrome. A clinicopathologic report of fifty fatal cases and a critique of the literature. Medicine 28 (1949) 59-141
6. Asbury A.K., Arnason B.G., and Adams R.D. The inflammatory lesion in idiopathic polyneuritis. Medicine 48 (1969) 173-215
7. Waksman B.H., and Adams R.D. Allergic neuritis: an experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjurants. J Exp Med 102 (1955) 213-235
8. Hartung H.P., Pollard J.D., Harvey G.K., et al. Immunopathogenesis and treatment of the Guillain-Barre syndrome-Part I. Muscle Nerve 18 (1995) 137-153
9. Hartung H.P., Pollard J.D., Harvey G.K., et al. Immunopathogenesis and treatment of the Guillain-Barre syndrome-Part II. Muscle Nerve 18 (1995) 154-164
10. Ropper A.H. The Guillain-Barre syndrome. N Engl J Med 326 (1992) 1130-1136
11. Kaldor J., and Speed B.R. Guillain-Barré syndrome and Campylobacter jejuni: a serological study. Br Med J 288 (1984) 1867-1870
12. Vriesendorp F.J., Mishu B., Blaser M., et al. Serum anti-bodies to GM1, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barré syndrome and controls: correlation and prognosis. Ann Neurol 34 (1993) 130-135
13. Enders U., Karch H., Toyka K.V., et al. The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders. Ann Neurol 34 (1993) 136-144
14. Tam C.C., Rodrigues L.C., and O'Brien S.J. Guillain-Barre syndrome associated with Campylobacter jejuni infection in England, 2000-2001. Clin Infect Dis 37 (2003) 307-310
15. Rees J.H., and Hughes R.A.C. Campylobacter jejuni and Guillain-Barré syndrome. Ann Neurol 35 2 (1994) 248
16. Feasby T.E., Gilbert J.J., Brown W.F., et al. An acute axonal form of Guillain-Barré polyneuropathy. Brain 109 (1986) 1115-1126
17. Feasby T.E., Hahn A.F., Brown W.F., et al. Severe axonal degeneration in acute Guillain-Barré syndrome: evidence of two different mechanism?. J Neurol Sci 116 (1993) 185-192
18. Griffin J.W., Li C.Y., Ho T.W., et al. Pathology of the motor-sensory axonal Guillain-Barre syndrome. Ann Neurol 39 (1996) 17-28
19. Griffin J.W., Li C.Y., Ho T.W., et al. Guillain-Barré syndrome in northern China: the spectrum of neuropathologic changes in clinically defined cases. Brain 118 (1995) 577-595
20. Ho T.W., Mishu B., Li C.Y., et al. Guillain-Barré syndrome in northern China: relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 118 (1995) 597-605
21. McKhann G.M., Cornblath D.R., Griffin J.W., et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 33 (1993) 333-342
22. Oomes P.G., Jacobs B.C., Hazenberg M.P.H., et al. Anti GM1 IgG antibodies and Campylobacter bacteria in Guillain-Barré syndrome: evidence of molecular mimicry. Ann Neurol 38 (1995) 170-175
23. Illa I., Ortiz N., Gallard E., et al. Acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann Neurol 38 (1995) 218-224
24. Yuki N., Taki T., Takahashi M., et al. Penner's serotype 4 of Campylobacter jejuni has a lipopolysaccharide that bears a GM1 ganglioside epitope as well as one that bears a GD1a epitope. Infect Immun 62 (1994) 2101-2103
25. Yuki N., Yamada M., Sato S., et al. Association of IgG anti-GD1a antibody with severe Guillain-Barre syndrome. Muscle Nerve 16 (1993) 642-647
26. Yuki N., Yoshino H., Sato S., et al. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter jejuni enteritis. Neurology 40 (1990) 1900-1902
27. Willison H.J., Veitch J., Patterson G., et al. Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J Neurol Neurosurg Psychiatr 56 (1993) 204-206
28. Yuki N., Sato S., Tsuji S., et al. Frequent presence of anti-GQ1b antibody in Fisher's syndrome. Neurology 43 (1993) 414-417
29. Willison H.J., and Veitch J. Immunoglobulin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller Fisher syndrome. J Neurochem 50 (1994) 159-165
30. Ropper A.H., Wijdicks E.F.M., and Truax B.T. Guillain-Barré Syndrome (1991), F.A. Davis, Publishers, Philadelphia
31. Cornblath D.R., McArthur J.C., Kennedy P.G.E., et al. Inflammatory demyelinating peripheral neuropathies associated with HTLV III infection. Ann Neurol 21 (1987) 32-40
32. Albers J.W., Donofrio P.D., and McGonagle T.K. Sequential electrodiagnostic abnormalities in acute inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 8 (1985) 528-539
33. Albers J.W., and Kelly Jr. J.J. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve 12 (1989) 435-451
34. Eisen A., and Humphreys P. The Guillain-Barré syndrome. A clinical and electrodiagnostic study of 25 cases. Arch Neurol 30 (1974) 438-443
35. McLeod J.G. Electrophysiological studies in the Guillain-Barre syndrome. Ann Neurol 9 Suppl (1981) 20-27
36. Olney R.K., and Aminoff M.J. Electrodiagnostic features of the Guillain-Barre syndrome: the relative sensitivity of different techniques. Neurology 40 (1990) 471-475
37. Miller R.G., Peterson G.W., Daube J.R., et al. Prognostic value of electrodiagnosis in Guillain-Barre syndrome. Muscle Nerve 11 (1988) 769-774
38. Triggs W.J., Cros D., Gominak S.C., et al. Motor nerve inexcitability in Guillain-Barré syndrome. Brain 115 (1992) 1291-1302
39. Nishimoto Y., Odaka M., Hirata K., et al. Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination. J Neuroimmunol 148 (2004) 200-205
40. Chalela J.A. Pearls and pitfalls in the intensive care management of Guillain-Barre syndrome. Semin Neurol 21 (2001) 399-405
41. Henderson R.D., Lawn N.D., Fletcher D.D., et al. The morbidity of Guillain-Barre syndrome admitted to the intensive care unit. Neurology 60 (2003) 17-21
42. Kieseier B.C., and Hartung H.P. Therapeutic strategies in the Guillain-Barre syndrome. Semin Neurol 23 (2003) 159-168
43. Hughes R.A.C., Newsom-Davis J.M., Perkin G.D., et al. Controlled trial of prednisolone in acute polyneuropathy. Lancet (1978) 750-753
44. Guillain-Barre Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barre syndrome. Lancet 341 (1993) 586-590
45. van Koningsveld R., Schmitz P.I., Meche F.G., et al. Dutch GBS study group. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet 363 (2004) 192-196
46. Hughes R.A., Wijdicks E.F., Barohn R., et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: immunotherapy for Guillain-Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 61 (2003) 736-740
47. Brettle R.P., Gross M., Legg N.J., et al. Treatment of acute polyneuropathy by plasma exchange. Lancet 2 8099 (1978) 1100
48. Osterman P.O., Lundemo G., Pirskanen R., et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 2 8415 (1984) 1296-1299
49. The Guillain-Barre Syndrome Study Group. Plasmapheresis and acute Guillain-Barre syndrome. Neurology 35 (1985) 1096-1104
50. McKhann G.M., Griffin J.W., Cornblath D.R., et al. Plasmapheresis and Guillain-Barre syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 23 (1988) 347-353
51. French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Efficiency of plasma exchange in Guillain-Barre syndrome: role of replacement fluids. Ann Neurol 22 (1987) 753-761
52. French Cooperative Group on Plasma Exchange in Guillain-Barre syndrome. Plasma exchange in Guillain-Barre syndrome: one-year follow-up. Ann Neurol 32 (1992) 94-97
53. Kleyweg R.P., van der Meche F.G.A., and Meulstee J. Treatment of Guillain-Barre syndrome with high-dose gammaglobulin. Neurology 38 (1988) 1639-1641
54. van der Meche F.G.A., and Schmitz P.I.M. Dutch Guillain-Barre Study Group: a randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med 326 (1992) 1123-1129
55. Castro L.H.M., and Ropper A.H. Human immune globulin infusion in Guillain-Barre syndrome: worsening during and after treatment. Neurology 43 (1993) 1034-1036
56. Irani D.N., Cornblath D.R., Chaudry V., et al. Relapse in Guillain-Barre syndrome after treatment with human immune globulin. Neurology 43 (1993) 872-875
57. Bril V., Ilse W.K., Pearce R., et al. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 46 (1996) 100-103
58. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 349 (1997) 225-230
59. Koul R., Chacko A., Ahmed R., et al. Ten-year prospective study (clinical spectrum) of childhood Guillain-Barre syndrome in the Arabian peninsula: comparison of outcome in patients in the pre- and post-intravenous immunoglobulin eras. J Child Neurol 18 (2003) 767-771
60. Mokrzycki M.H., and Kaplan A.A. Therapeutic plasma exchange: complications and management. Am J Kidney Dis 23 (1994) 817-827
61. Rodnitzky R.L., and Goeken J.A. Complications of plasma exchange in neurologic patients. Arch Neurol 39 (1982) 350-354
62. Bouget J., Chevret S., et al. Plasma exchange morbidity in Guillain-Barre syndrome: results from the French prospective, double-blind, randomized, multicenter study. Crit Care Med 21 (1993) 651-658
63. Thornton C.A., and Ballow M. Safety of intravenous immunoglobulin. Arch Neurol 50 (1993) 135-136
64. Duhem C., Dicato M.A., and Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol 97 Suppl 1 (1994) 79-83
65. Bjoro K., Froland S.S., Yun Z., et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 331 (1994) 1607-1611
66. Tan E., Hajinazarian M., Bay W., et al. Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol 50 (1993) 137-139
67. Silbert P.L., Knezevic W.V., and Bridge D.T. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology 42 (1992) 257-258
68. Steg R.E., and Letkowitz D.M. Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology 44 (1994) 1180-1181
69. Woodruff R.K., Grigg A.P., Firkin F.C., et al. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 328 (1986) 217-218
70. Dalakas M.C. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 44 (1994) 223-226
71. Scribner C.L., Kapit R.M., Phillips E.T., et al. Aseptic meningitis and intravenous immunoglobulin therapy. Ann Intern Med 121 (1994) 305-306
72. Sekul E.A., Cupler E.J., and Dalakas M.C. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 121 (1994) 259-262
73. DeVlieghere F.C., Peetermans W.E., and Vermylen J. Aseptic granulocytic meningitis following treatment with intravenous immunoglobulin. Clin Infect Dis 18 (1994) 1008-1010
74. Voltz R., Rosen F.V., Yousry T., et al. Reversible encephalopathy with vasospasm in a Guillain-Barré syndrome patient associated with intravenous immunoglobulin. Neurology 46 (1996) 250-251
75. Martin C.N., and Hughes R.A.C. Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatr 62 (1997) 310-318
76. Boulton A.J., Gries F.A., and Jervell J.A. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet Med 15 (1998) 508-514
77. Rosenberg N.R., Portegies P., deVisser M., et al. Diagnostic investigation of patients with chronic polyneuropathy: evaluation of a clinical guideline. J Neurol Neurosurg Psychiatr 71 (2001) 205-209
78. Davies L., Spies J.M., Pollard J.D., et al. Vasculitis confined to peripheral nerves. Brain 119 (1996) 1441-1448
79. Dyck P.J., Berstead T.J., Coon D.L., et al. Nonsystemic vasculitic neuropathy. Brain 110 (1987) 843-854
80. Dyck P.J.B., Norell J.E., and Dyck P.J. Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy. Neurology 53 (2000) 2113-2121
81. Saperstein D.S., Katz J.S., Amato A.A., et al. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 24 (2001) 311-324
82. Russell J.W., and Feldman E.L. Impaired glucose tolerance-does it cause neuropathy. Muscle Nerve 24 (2001) 1109-1112
83. Gabriel C.M., Hughes R.A.C., Howard R., et al. Prospective study of the usefulness of sural nerve biopsy. J Neurol Neurosurg Psychiatr 68 (2000) 442-446
84. Reilly M.M. Classification of the hereditary motor and sensory neuropathies. Curr Opin Neurol 13 (2000) 561-564
85. Nobile-Orazio E. Multifocal motor neuropathy. J Neuroimmunol 115 (2001) 4-18
86. Sindrup S.H., and Jensen T.S. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 83 (1999) 389-400
87. Felz M.W., Smith C.D., and Swift T.R. A six-year-old girl with tic paralysis. N Engl J Med 342 (2000) 90-94
88. Wolfe G.I., and Barohn R.J. Cryptogenic sensory and sensorimotor polyneuropathies. Semin Neurol 18 (1998) 105-111
89. Wolfe G.I., El-Feky W.H., Katz J.S., et al. Antibody panels in idiopathic polyneuropathy and motor neuron disease. Muscle Nerve 20 (1997) 1275-1283
90. Amato A.A., and Collins M.P. Neuropathies associated with malignancy. Semin Neurol 18 (1998) 125-144
91. Mauermann M.L., and Burns T.M. The evaluation of chronic axonal polyneuropathies. Semin Neurol 28 (2008) 133-151